Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Total 3Q 2023 product revenue of $57.8 million, representing 244% year-over-year growth Auvelity ® 3Q 2023 net product sales of $37.7 million, representing 36% quarter-over-quarter growth Sunosi ® 3Q 2023 net product revenue of $20.1 million, representing 20% year-over-year growth SYMPHONY Phase 3 trial of AXS-12 in narcolepsy on track for completion of enrollment in 4Q 2023; topline results expected in 1Q 2024 Phase 3 trial of solriamfetol in binge eating disorder on track for initiation in 4Q 2023 Phase 3 trial of solriamfetol in shift work disorder on track for initiation in 1Q 2024 NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine both expected in 1H 2024 Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023. “Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Axsome's headquarters to be lit in teal as part of the Alzheimer's Foundation of America awareness campaign Axsome's headquarters to be lit in teal as part of the Alzheimer's Foundation of America awareness campaign

Axsome Therapeutics and the Global Alzheimer's Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer's Disease Awareness Month 2023

Agilysys

Cogent Communications Holdings

It's the dream of every investor to uncover stocks with the potential to grow tenfold within a short span. While it may sound like a lofty goal, the article reveals that it's not just a pipe dream.

Riding the Wave: 3 Stocks That Can 10X by 2025

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced a presentation of data from its ACCORD Phase 3 clinical trial of AXS-05, a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, in patients with Alzheimer's disease agitation (ADA), at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Conference, being held in Boston from Oct. 24-27.

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Conference

Axsome Therapeutics' Auvelity is experiencing strong sales growth in the Major Depressive Disorder space, with sales of $27.6 million in the last quarter. Auvelity offers rapid onset of symptom improvement, providing swift relief for patients seeking relief from depression. The drug's market exclusivity is expected to last until 2034, and its sales projections have been increased to $1.2 billion.

Axsome Update: Buy At Dips And Hold Forever

Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

Vertex Pharmaceuticals

Vertex Pharmaceuticals is awaiting a regulatory decision on what may become its next blockbuster. Axsome Therapeutics aims to launch several products over the next few years.

2 Top Biotech Stocks to Buy in October

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining patient advocacy organizations, including the National Alliance on Mental Illness (NAMI), to promote awareness of the importance of mental health during Mental Illness Awareness Week (MIAW), recognized on Oct. 1-7, 2023.

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining the global narcolepsy advocacy community, including more than 20 global patient advocacy organizations across six continents, to raise awareness of the impact that narcolepsy has on World Narcolepsy Day, Sept. 22, 2023.

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

Exelixis

Exelixis is using its expertise in cancer medicines to move beyond its current best-selling product. Axsome Therapeutics should look like a very different company within the next few years.

2 Top Biotech Stocks Defying the Bear Market

Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Why Is Axsome (AXSM) Up 8.6% Since Last Earnings Report?

Hormel Foods

Tilray Brands

Axsome's two new products have the potential to generate exceptional growth. Hormel Foods' resilience is impressive, even in an inflationary market.

These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?

Beam Therapeutics

Brookfield Renewable Partners

Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics' base-editing technology could be a huge moneymaker over time.

Got $200? 3 Growth Stocks to Buy That Could Double Your Money

U.S. Bancorp

Axsome Therapeutics has major catalysts on the way. U.S. Bancorp remains a bargain, even after its strong rebound.

3 Explosive Stocks to Buy Right Now

Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.

Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Mark Jacobson - IR Herriot Tabuteau - CEO Nick Pizzie - CFO Lori Englebert - EVP, Commercial and Business Development Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Joon Lee - Truist Securities Jason Gerberry - Bank of America David Amsellem - Piper Sandler Vikram Purohit - Morgan Stanley Yatin Suneja - Guggenheim Partners Joseph Thome - TD Cowen Matt Kaplan - Ladenburg Thalmann Graig Suvannavejh - Mizuho Securities Myles Minter - William Blair Operator Hello, and welcome to the Axsome Therapeutics Second Quarter Results Conference Call and Webcast.

Axsome Therapeutics, Inc. (AXSM) Q2 2023 Earnings Call Transcript

Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter cash balance of $468.8 million FOCUS Phase 3 trial of solriamfetol in attention-deficit hyperactivity disorder initiated Positive FDA pre-IND meeting feedback received for two new potential indications for solriamfetol: Phase 3 trial initiations planned for binge eating disorder in 4Q 2023, and shift work disorder in 1Q 2024 Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2023. “We exhibited strong financial performance and pipeline advancement in the second quarter.

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Arcturus Therapeutics

Emergent BioSolutions

Novavax

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

AbbVie

AbbVie's future is bright despite a recent major patent cliff. Axsome Therapeutics' pipeline will lead to more approvals soon.

Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond

Axsome Therapeutics' novel treatments for central nervous system disorders gain traction, with promising revenues from drugs Auvelity and Sunosi. Despite the current lack of profitability, Axsome shows potential for significant growth, buoyed by public offerings and a healthy cash position. The successful launch of Auvelity presents an enticing opportunity for long-term investors, moving the previous recommendation from "Hold" to "Buy".

Axsome Therapeutics: 'Buy' The Auvelity Launch (Rating Upgrade)

Axsome Therapeutics' current drugs and pipeline programs look especially promising. Brookfield Renewable could double in six years if it hits the low end of its projected growth range.

Got $500? 3 Growth Stocks to Buy That Could Double Your Money

Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

Axsome (AXSM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axsome (AXSM) Upgraded to Strong Buy: Here's What You Should Know

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

News for Axsome Therapeutics Stock (AXSM)